Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.53 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24740103 | 0.87 | ALOX15 (0.58) | ALOX15CNR1HRH4NUDT1 | |
| SCHEMBL25768556 | 0.83 | MEN1 (0.47) | ALOX15BRD4METAP2CNR1HRH4 | |
| SCHEMBL24740405 | 0.82 | ALOX15 (0.50) | ALOX15MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL24740100 | 0.81 | ALOX15 (0.58) | ALOX15HRH4NUDT1DRD2DRD3 | |
| SCHEMBL24019772 | 0.80 | ALOX15 (0.53) | ALOX15HRH4MEN1KMT2A | |
| SCHEMBL25812181 | 0.79 | HRH4 (0.43) | HRH4MEN1KMT2A | |
| SCHEMBL3106434 | 0.77 | CDK1 (0.54) | ALOX15HRH4MEN1KMT2A | |
| SCHEMBL24740852 | 0.77 | ALOX15 (0.60) | ALOX15BRD4HRH4NUDT1DRD2 | |
| SCHEMBL3089645 | 0.77 | HPGD (0.53) | ALOX15HRH4MEN1KMT2A | |
| SCHEMBL24740102 | 0.76 | ALOX15 (0.63) | ALOX15HRH4HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | ALOX15 1455/4885BRD4 3186/4885METAP2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.